Emicizumab, a bispecific antibody that bridges clotting factors IX and X, restores factor VIII function and prevents bleeding in hemophilia A with infrequent injections.
The indications, pharmacokinetics, and therapeutic guidelines for available coagulation products are reviewed. Patients with hemophilia, von Wille-brand's disease (VWD), or acquired inhibitors to ...
Sponsored by: Diagnostica Stago, Inc. In clinical laboratory settings, coagulation factor tests are routinely conducted to identify inherited or acquired deficiencies in patients suspected of an ...
A new review article illuminates why physicians should keep coagulation disorders in mind when evaluating patients with heavy abnormal uterine bleeding. Physicians treating patients with heavy ...
A novel gene therapy for hemophilia A led to sustained expression of the clotting factor those patients lack, resulting in a reduction—or in some cases complete elimination—of painful and potentially ...
All that most laymen know about hemophilia is that it is an odd and dangerous disease of the blood that strikes men only, although it is transmitted by women. Medical researchers have learned a great ...
The European Medicines Agency (EMA) this week recommended granting a marketing authorization for Altuvoct (efanesoctocog alfa) for the treatment and prophylaxis of bleeding in patients with hemophilia ...
Blood coagulation factor XIII (FXIII) is the final transglutaminase in the clotting cascade, responsible for cross-linking fibrin polymers and stabilising the haemostatic plug. In plasma it circulates ...
During pregnancy, the human embryo is initially supplied with nutrients through the yolk sac; later, the placenta takes over ...
Medically reviewed by Steffini Stalos, DO Key Takeaways Blood clotting disorders can be inherited or acquired and lead to ...
Hemophilia A and B are similar conditions that affect the blood’s ability to clot. They typically occur due to gene variations that affect different blood clotting factors. Hemophilia is a group of ...